#VAV1
Yichang Humanwell Pharmaceutical patents new VAV1 degradation inducers - BioWorld News
Yichang Humanwell Pharmaceutical patents new VAV1 degradation inducers - BioWorld News
Yichang Humanwell Pharmaceutical patents new VAV1 degradation inducers  BioWorld News
www.bioworld.com
November 14, 2026 at 8:06 PM
The licensing deal for oral VAV1 degrader EVO570 could reach about $1.1 billion in milestones, with a Phase 1 trial starting soon.

Link as first comment.

#longevity #biotech #drugdevelopment #clinicaltrials #VAV1
November 16, 2026 at 9:22 AM
Deal tracker: Hinova licenses VAV1 molecular glue degrader HP570 (EVO570) to Evommune outside Greater China: $30M upfront ($20M cash + $10M in warrants), up to $1.07B in milestones, plus tiered royalties. Evommune plans a mid-stage RA study in 2027.
https://inlightbio.com/news/?type=lic
November 17, 2026 at 12:38 PM
Compass Pathways filed its COMP360 NDA in treatment-resistant depression, Evommune took a $1.13B VAV1 molecular glue deal, Flagship and Gates put $25M into global health, NervGen won Breakthrough.
https://openbionews.com/analysis/ai-in-bio-weekly-review-2026-11-06-to-12/
AI in Bio Weekly Review: Compass Pathways
The seven-day window spanning November 6–12, 2026 delivered watershed milestones across neuropsychiatry, targeted protein degradation, and global health biotech: Compass Pathways completed its landmark FDA NDA submission for COMP360 psilocybin in treatment-resistant depression; Evommune in-licensed
openbionews.com
November 14, 2026 at 3:01 AM
🚨 JUST IN: $EVMN
Evommune in-licenses Hinova's VAV1 degrader EVO570 for $20M cash, $10M warrants, up to $1.1B milestones

#SEC #stocks #investing #EVMN #Mergers
🔗 secwatch.observer
November 4, 2026 at 11:12 PM
Today we announced a milestone achievement associated with the initiation of the second Ph 2 study of MRT-6160 (DDY391), a VAV1-directed MGD, in people living with active moderate to severe psoriatic arthritis: bit.ly/4iJgew2
October 28, 2026 at 11:04 AM
#CCCC C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the…

https://www.stocktitan.net/news/CCCC/c4-therapeutics-unveils-expansion-of-discovery-platform-capabilities-s601qrnbwi5z.html?utm_source=stocktitan-bluesky&utm_medium=social
C4 Therapeutics Unveils Expansion of Discovery Platform Capabilities Utilizing Target-Centric Approach to Accelerate the Identification of Novel Molecular Glue Degraders
C4 Therapeutics (CCCC) expanded its drug-discovery platform with a DNA-encoded library designed to identify molecular glue degraders using a target-first approach.The library integrates the company’s cereblon-binding compounds into its TORPEDO platform. C4 Therapeutics said the technology has delivered promising initial compounds against selected targets within four months. Testing identified known and novel initial compounds for VAV1, plus compounds for additional undisclosed targets. The company does not plan to advance VAV1 without a partner. Its priorities remain clinical development of cemsidomide and discovery work on undisclosed targets involved in inflammation, neuroinflammation and neurodegenerative diseases.
www.stocktitan.net
October 29, 2026 at 11:00 AM
InnoCare's US20260209204A1 discloses CRBN-based VAV1 molecular glue degraders. Inserting one CH2 between the 2-pyridone and the terminal ring takes DC50 from >2,000 nM to 21 nM, and a 5-cyclopropyl on the pyridine brings it to 2.4 nM (Dmax 98%). #MedChem
aurio9923.com/en/2026/10/2...
Structure–Activity Relationships of InnoCare’s VAV1 Molecular Glue Degraders | US20260209204A1
A look at the structure–activity relationships of InnoCare’s VAV1 molecular glue degraders, based on data from the patent publication.
aurio9923.com
October 26, 2026 at 1:49 PM
Insilico Medicine nominates ISM9546, an oral VAV1 degrader designed with generative AI, as a preclinical candidate for autoimmune disease.

Link as first comment.

#longevity #geroscience #InsilicoMedicine #ISM9546 #autoimmunedisease
October 22, 2026 at 11:25 AM
Compartment-specific PPARδ activity controls the outcome of cancer-immune cell competition and immunotherapy efficacy
To assess how PPARδ activity influences cancer–immune cell competition, we generated gain-of-function (GOF) genetic models overexpressing the VP16/VP64–PPARδ fusion protein (PPARδ-GOF) in either cancer cells or immune cells. First, we overexpressed the PPARδ-GOF in carcinogen-induced MC38 colorectal adenocarcinoma cell line (PPARδ-cGOF), which generates microsatellite instable (MSI) tumors with high mutational burden and immune infiltration. Next, we generated Vav1-cre+ VP16–PPARδ+ mice that overexpress PPARδ-GOF in all immune cells (PPARδ-iGOF; Extended Data Fig. 1a). As reported11,12,13,14,15, selective activation of PPARδ in cancer cells promoted their growth in wild-type (WT) mice. Strikingly, immune cell-specific activation in PPARδ-iGOF mice inhibited the growth of both control and PPARδ-cGOF tumors (Fig. 1a and Extended Data Fig. 1b). To dissect how cancer-intrinsic or immune-intrinsic PPARδ activation influences the tumor microenvironment (TME), we performed single-cell RNA sequencing (scRNA-seq) and single-cell assay for transposase-accessible chromatin using sequencing (scATAC-seq; Extended Data Fig. 1c–m). Genes involved in survival, proliferation and immunosuppression were upregulated in PPARδ-cGOF MC38 cancer cells in WT mice (Fig. 1b). In contrast, immune-intrinsic PPARδ activation promoted expression of apoptosis, negative regulation of proliferation and immune recognition-related genes in MC38 cancer cells with active PPARδ (cGOF + iGOF; Fig. 1c,d). WT CD8+ T cells in PPARδ-cGOF showed increased expression...
www.nature.com
October 14, 2026 at 9:59 PM
個人情報保護委員会が機能しているのか疑問なのだ。破産者マップ等にはきちんと対処しているのに、AIという言葉が入るとゆるゆるな基準。AIといえば許される風潮がなんだかなぁ~(・・*)。。oO(想像中)

www.youtube.com/watch?v=VAv1...
改正個人情報保護法はEUの保護水準を満たしているのか? 弁護士らがEUに意見書提出し十分性認定の是非を問います。 10月6日記者会見
YouTube video by 全国保険医団体連合会公式チャンネル
www.youtube.com
October 9, 2026 at 1:10 AM
相次ぐ情報漏洩 弁護士がEUに提訴

改正個人情報保護法はEUの保護水準を満たしているのか? 弁護士らがEUに意見書提出し十分性認定の是非を問います。 10月6日記者会見

#保団連
全国保険医団体連合会公式チャンネル
www.youtube.com/watch?v=VAv1...
改正個人情報保護法はEUの保護水準を満たしているのか? 弁護士らがEUに意見書提出し十分性認定の是非を問います。 10月6日記者会見
YouTube video by 全国保険医団体連合会公式チャンネル
www.youtube.com
October 8, 2026 at 6:28 AM
Drug developers must balance the speed of predictive modeling with the risk of off-target effects, such as the unintended degradation of LIMD1.

Medicine · Phys.org
#Medicine #MedSky
AI structure prediction speeds discovery of 'molecular glues' to treat disease
Researchers combined high-throughput proteomics with computational modeling to discover molecular glues that direct the VAV1 protein to cellular disposal machinery. The platform predicted how the molecules bind target proteins without prior experimental structures, which helped chemists design…
aibusinesslens.com
October 1, 2026 at 2:00 PM
A molecular glue lowered VAV1 and suppressed activation in primary human T cells. AI predicted its contact point on VAV1 before lab tests confirmed it. doi.org/hckxvs
AI structure prediction speeds discovery of 'molecular glues' to treat disease
A Baylor College of Medicine-led team has developed a strategy that combines the analysis of thousands of proteins with artificial intelligence to accelerate the discovery of small molecules called molecular glues to treat disease.
phys.org
September 29, 2026 at 8:30 PM
September 17, 2026 at 7:09 PM
Today we announced a milestone achievement associated with the initiation of a Ph 2 study of MRT-6160 (DDY391), a VAV1-directed MGD, in participants living with Sjögren’s disease – the first of several studies expected across immune-mediated diseases: bit.ly/4A0rOcF
September 8, 2026 at 11:30 AM
🚨 $GLUE
On September 8, 2026, Monte Rosa Therapeutics, Inc. issued a press release announcing the achievement of a milestone associated with the initiation of a Phase 2 clinical study for the VAV1-directed molecular glue degrader MRT-6160 (DDY391) in participants with Sjögren’s disease.
SEC Filing: GLUE
Click to view the official SEC document.
www.sec.gov
September 8, 2026 at 11:03 AM
Y-CH: HIV-1-infected Jurkat T cell clones with integration in RAP1B, VAV1, EEF2K, INPPL1, or non-genic #ccvi24
September 6, 2024 at 2:57 PM
❗ 📚💡 Another paper going outside cannonical G-loop degron:

Beyond the G-Loop: CRBN Molecular Glues Potently Target VAV1 via a Novel SH3 RT-Loop Degron

www.biorxiv.org/content/10.1...

#TPD #Targeted_Protein_Degradation #CRBN
Beyond the G-Loop: CRBN Molecular Glues Potently Target VAV1 via a Novel SH3 RT-Loop Degron
This study reports the discovery and characterization of novel CRBN molecular glues that selectively induce the proteasomal degradation of the hematopoietic-specific signaling protein VAV1, a key targ...
www.biorxiv.org
June 10, 2025 at 7:20 PM